CXCR4 Expression in Early Breast Cancer and Risk of Distant Recurrence

Varga, Andrea; Xia, Weiya; Conforti, Rosa; Wei, Yongkun; Boulet, Thomas; Tomasic, Gorana; Spielmann, M.; Zoubir, M.; Berrada, Narjiss; Arriagada, R.; Hortobágyi, Gabriel N.; Hung, Mien‐Chie; Pusztai, Lajos; Delaloge, Suzette; Michiels, Stefan; Cristofanilli, Massimo

doi:10.1634/theoncologist.2009-0161

Cited by 62 publications

(46 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings are consistent with those previously reported on breast, prostate cancer and hepatocarcinoma in which a correlation was seen between CXCR4 expression and BM [38,39,40]. Andre et al [38] showed that CXCR4 expression in the primary tumor could be used as an indicator of a high risk for BM in early breast cancer patients.…”

Section: Discussionsupporting

confidence: 93%

The Role of CXCR4 in the Prediction of Bone Metastases from Breast Cancer: A Pilot Study

et al. 2011

View full text Add to dashboard Cite

Objective: The chemokine receptor CXCR4 is involved in tumor growth and homing of cancer cells to distant sites. The aim of our retrospective case-control study was to evaluate whether CXCR4 expression is more effective than conventional markers (estrogen receptor and HER-2) in predicting bone relapse in breast cancer. Methods: CXCR4 expression was evaluated by immunohistochemical staining in paraffin-embedded tissue sections of primary breast cancers from 20 patients with bone metastases (BM), 10 with visceral metastases (VM) and 10 with no evidence of disease (NED) at a median follow-up of 10.5 years (range 10.1–11.8). Results: Cytoplasmic CXCR4 expression was high in BM patients (45%, 95% CI 23–67), much lower in NED patients (10%, 95% CI 0–29) and negative in the VM group. CXCR4 coexpression in the nucleus and cytoplasm was observed in about half of the BM patients (45%) but never in NED or VM patients (p = 0.013). Conversely, estrogen receptor-positive and HER-2-negative status identified 80 and 95% of bone relapse patients, respectively, but did not discriminate between cases and controls. Conclusions: Our results suggest a pivotal role of CXCR4 expression as a predictor of BM in primary breast cancer. A larger study is ongoing to confirm these results.

show abstract

Section: Discussionsupporting

confidence: 93%

The Role of CXCR4 in the Prediction of Bone Metastases from Breast Cancer: A Pilot Study

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Recent studies demonstrate that the expression of specific molecules, including chemokine receptors as well as claudin-2, CCN3, and tenascin-C, correlate with and/or enhance metastasis to distinct sites (119,(136)(137)(138). The chemokine CXCL12 is expressed in bone marrow, and expression of its cognate receptor CXCR4 on breast tumor cells is correlated with an increased risk of metastasis to bone (139). Interestingly, cell lines selected for enhanced metastasis to bone display a specific transcriptional signature (including elevated CXCR4) that is also present in subsets of cells from the parental tumor cell population (140), suggesting that subpopulations of cells capable of metastasis to specific sites form part of the initial spectrum of heterogeneity in the primary tumor.…”

Section: Differential Preference For Sites Of Metastasesmentioning

confidence: 99%

Breast cancer — one term, many entities?

Bertos¹,

Park²

2011

J. Clin. Invest.

188

140

View full text Add to dashboard Cite

Breast cancer, rather than constituting a monolithic entity, comprises heterogeneous tumors with different clinical characteristics, disease courses, and responses to specific treatments. Tumor-intrinsic features, including classical histological and immunopathological classifications as well as more recently described molecular subtypes, separate breast tumors into multiple groups. Tumor-extrinsic features, including microenvironmental configuration, also have prognostic significance and further expand the list of tumor-defining variables. A better understanding of the features underlying heterogeneity, as well as of the mechanisms and consequences of their interactions, is essential to improve targeting of existing therapies and to develop novel agents addressing specific combinations of features.

show abstract

“…But there are data that do not confirm the negative impact of CXCR4 on survival. So, Andre et al [14] have shown that CXCR4 expression was not associated with clinical characteristics of breast cancer, and it was not prognostic factor for overall survival, but significantly higher risk for bone metastasis in patients with CXCR4-positive tumors which was observed.…”

Section: Introductionmentioning

confidence: 92%

CXCR4 Expression in Gastric Cancer and Bone Marrow: Association with Hypoxia-Regulated Indices, Disseminated Tumor Cells, and Patients Survival

Osinsky

Kovelskaya

Bubnovskaya

et al. 2015

Journal of Cancer Research

View full text Add to dashboard Cite

Aim. The analysis of the association of CXCR4 expression in gastric cancer (GC) and bone marrow (BM) with clinical characteristics. Patients and Methods. 65 patients with GC were investigated. Immunohistochemistry, immunocytochemistry, NMR-spectroscopy, and zymography were used. Results. CXCR4 was expressed in 78.5% of GC specimens and correlated with tumor hypoxia ( < 0.05), VEGF expression ( < 0.01), and gelatinases activity ( < 0.05). CXCR4-positive cells in GC were detected in 80% of patients with disseminated tumor cells (DTCs). Overall survival (OS) of patients with CXCR4-positive tumors was poorer than that of patients with CXCR4-negative tumors ( = 0.037). The CXCR4-positive cells in BM were found in 46% of all patients and in 56% of patients with DTCs. CXCR4 expression in BM was not associated with OS. Risk of unfavourable outcome is increased in patients with CXCR4-positive tumors ( < 0.05). CXCR4 expression in BM was positively associated with DTCs, especially in patients with M 0 category. Risk of unfavourable outcome is increased in patients with M 0 category and with both CXCR4-positive BM and DTCs ( = 0.03). Conclusions. CXCR4 expression in tumor was positively correlated with hypoxia level and VEGF expression in tumor as well as OS. CXCR4 expression in BM is associated with DTCs.

show abstract

CXCR4 Expression in Early Breast Cancer and Risk of Distant Recurrence

Cited by 62 publications

References 29 publications

The Role of CXCR4 in the Prediction of Bone Metastases from Breast Cancer: A Pilot Study

The Role of CXCR4 in the Prediction of Bone Metastases from Breast Cancer: A Pilot Study

Breast cancer — one term, many entities?

CXCR4 Expression in Gastric Cancer and Bone Marrow: Association with Hypoxia-Regulated Indices, Disseminated Tumor Cells, and Patients Survival

Contact Info

Product

Resources

About